Sarepta Therapeutics (SRPT) Shares Resume Trading; Now Up 82% on FDA Eteplirsen Approval
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Sarepta Therapeutics (NASDAQ: SRPT) is up 82% after re-opening on accelerated approval for eteplirsen
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stocks with Implied Volatility Movement
- Array BioPharma (ARRY) Could Trade up 50-75% Amid Positive COLUMBUS Trial Results - JPMorgan
- Volatility and Volume movement
Create E-mail Alert Related CategoriesFDA, Momentum Movers, Trader Talk, Trading Halts
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!